Stand Up To Cancer will receive a $4 million grant from Mirati Therapeutics Inc. to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst program.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
